Sign inJoin waitlistJoin the waitlist

Peter O'Dwyer

Director, Developmental Therapeutics Program, Abramson Cancer Center · University of Pennsylvania Health System

Credentials: · · · · ·

History

Developmental Therapeutics Program · University of Pennsylvania Health System
Present

Hematology and Medical Oncology
University of Maryland Medical Center
1989–1992
National Cancer Institute
1987–1989
Waterbury Hospital
1984–1987
University of Maryland Medical Center
1981–1984
Saint Patrick's Hospital and Health Sciences Center
1978–1981
Internal Medicine
Greater Baltimore Medical Center
1975–1978
School of Medicine, Trinity College Dublin
1971–1975

Research

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy · 2016 · 4,439 citations
Inhibition of mutated, activated BRAF in metastatic melanoma
New England Journal of Medicine · 2010 · 2,847 citations
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative…
Journal of Clinical Oncology · 2007 · 1,811 citations

Keith Flaherty
64 papers · 3 as a fellow
SH
Stanley Hamilton
43 papers
LH
Lyndsay Harris
40 papers
Barbara Conley
35 papers
Carlos Arteaga
34 papers
BG
Bruce Giantonio
33 papers
Al Benson
30 papers
RO
Robert Ozols
30 papers
James Stevenson
28 papers · 6 as a fellow
AC
Alice Chen
26 papers
EM
Edith Mitchell
26 papers
RC
Robert Comis
24 papers

Grants

ECOG-ACRIN Network Group Operations Center
National Cancer Institute · U10
Contact PI · $115.8M · Ecog-Acrin Medical Research Foundation
2014–2032
ECOG-ACRIN NCORP Research Base
National Cancer Institute · UG1
PI · $150.4M · Ecog-Acrin Medical Research Foundation
2014–2027
Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making
Food and Drug Administration · U01
Contact PI · $4.5M · Ecog-Acrin Medical Research Foundation
2023–2026
Penn Quantitative MRI Resource for Pancreatic Cancer
National Cancer Institute · U24
PI · $3M · University of Pennsylvania
2018–2024

Clinical trials

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Principal investigator · Terminated · Early phase 1
Abramson Cancer Center at Penn Medicine
2020–2022
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Principal investigator · Completed · Phase 1
Abramson Cancer Center at Penn Medicine
2017–2020
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
Principal investigator · Terminated · Phase 1
Abramson Cancer Center at Penn Medicine
2017–2022
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
Principal investigator · Enrolling by invitation
Abramson Cancer Center at Penn Medicine
2015–2035